CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
16.51 CAD
+0.7 (+4.43%)
Taking everything into account, CPH scores 6 out of 10 in our fundamental rating. CPH was compared to 34 industry peers in the Pharmaceuticals industry. While CPH has a great profitability rating, there are some minor concerns on its financial health. CPH is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
CPH had positive earnings in the past year.
CPH had a positive operating cash flow in the past year.
Each year in the past 5 years CPH has been profitable.
CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.97%, CPH belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
CPH's Return On Equity of 11.10% is amongst the best of the industry. CPH outperforms 88.24% of its industry peers.
CPH has a Return On Invested Capital of 5.17%. This is amongst the best in the industry. CPH outperforms 85.29% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 7.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROIC | 5.17% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
Looking at the Profit Margin, with a value of 25.52%, CPH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of CPH has grown nicely.
With an excellent Operating Margin value of 20.32%, CPH belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
In the last couple of years the Operating Margin of CPH has declined.
Looking at the Gross Margin, with a value of 73.79%, CPH belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
CPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, CPH has more shares outstanding
Compared to 5 years ago, CPH has less shares outstanding
CPH has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.63 indicates that CPH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.63, CPH belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
CPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, CPH is in line with its industry, outperforming 52.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.63 |
ROIC/WACC0.57
WACC9.15%
2.3 Liquidity
A Current Ratio of 1.72 indicates that CPH should not have too much problems paying its short term obligations.
With a Current ratio value of 1.72, CPH perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
CPH has a Quick Ratio of 1.41. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
CPH's Quick ratio of 1.41 is in line compared to the rest of the industry. CPH outperforms 52.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
The earnings per share for CPH have decreased strongly by -48.31% in the last year.
The Earnings Per Share has been growing by 12.47% on average over the past years. This is quite good.
The Revenue has grown by 114.76% in the past year. This is a very strong growth!
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
The Earnings Per Share is expected to grow by 14.85% on average over the next years. This is quite good.
Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 21.67% on average per year.
EPS Next Y105.37%
EPS Next 2Y21.71%
EPS Next 3Y14.85%
EPS Next 5YN/A
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CPH is valuated quite expensively with a Price/Earnings ratio of 26.21.
82.35% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CPH to the average of the S&P500 Index (27.41), we can say CPH is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 17.97, the valuation of CPH can be described as rather expensive.
79.41% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.88. CPH is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.21 | ||
| Fwd PE | 17.97 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CPH is valued a bit cheaper than 61.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 18.97 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPH may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 14.85% in the coming years.
PEG (NY)0.25
PEG (5Y)2.1
EPS Next 2Y21.71%
EPS Next 3Y14.85%
5. Dividend
5.1 Amount
CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (9/18/2025, 7:00:00 PM)
16.51
+0.7 (+4.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners4.67%
Ins Owner ChangeN/A
Market Cap418.03M
Analysts77.78
Price Target17.87 (8.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)2
Avg EPS beat(4)-14.13%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)6
Avg EPS beat(8)67.23%
EPS beat(12)10
Avg EPS beat(12)112.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)3
Avg Revenue beat(4)31.13%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)115.89%
Revenue beat(8)5
Avg Revenue beat(8)22.37%
Revenue beat(12)5
Avg Revenue beat(12)11.03%
Revenue beat(16)5
Avg Revenue beat(16)5.52%
PT rev (1m)10.75%
PT rev (3m)9.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)46.4%
EPS NY rev (3m)46.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.78%
Revenue NY rev (3m)-1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.21 | ||
| Fwd PE | 17.97 | ||
| P/S | 6.37 | ||
| P/FCF | N/A | ||
| P/OCF | 14.36 | ||
| P/B | 2.77 | ||
| P/tB | 18.16 | ||
| EV/EBITDA | 18.97 |
EPS(TTM)0.63
EY3.82%
EPS(NY)0.92
Fwd EY5.56%
FCF(TTM)-3.21
FCFYN/A
OCF(TTM)1.15
OCFY6.97%
SpS2.59
BVpS5.96
TBVpS0.91
PEG (NY)0.25
PEG (5Y)2.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROCE | 7.18% | ||
| ROIC | 5.17% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 22.78% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 1132.75% | ||
| Cap/Sales | 168.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.25% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 5.63 |
F-Score5
WACC9.15%
ROIC/WACC0.57
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
EPS Next Y105.37%
EPS Next 2Y21.71%
EPS Next 3Y14.85%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year115.73%
EBIT Next 3Y39.42%
EBIT Next 5YN/A
FCF growth 1Y-558.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3Y12.28%
OCF growth 5Y19.77%